

# Avelumab

**Catalog No: tcsc0030892**



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 20mg



## Specifications

**CAS No:**

1537032-82-8

**Formula:**

N/A

**Pathway:**

Immunology/Inflammation

**Target:**

PD-1/PD-L1

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

Anti-Human PD-L1, Human Antibody;MSB 0010718C; MSB0010718C

**Observed Molecular Weight:**

1000

## Product Description

Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.

IC50 & Target: PD-1/PD-L1<sup>[1]</sup>

**In Vitro:** Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold ( $P=0.01$ ) in JHC7 cells relative to isotype control. When the cells are treated with IFN- $\gamma$ , Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold;  $P=0.001$ ), UM-Chor1 (7.34-fold;  $P[1]$ ). Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8<sup>+</sup> T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs)<sup>[2]</sup>.

**In Vivo:** Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant ( $P[3]$ ).

Avelumab

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!